This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
by Zacks Equity Research
Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
June PPI Weak at -0.2%, COVID Drug Adds Promise
by Mark Vickery
June Producer Price Index headline of -0.2% was a big miss from the +0.4% consensus and the +0.4% headline for May.
Gilead Starts Testing Remdesivir Inhaled Version for Coronavirus
by Zacks Equity Research
Gilead (GILD) begins a phase I study to evaluate the safety, tolerability and pharmacokinetics of an investigational, inhaled solution of remdesivir for coronavirus.
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Regeneron Initiates Studies on Experimental Coronavirus Drug
by Zacks Equity Research
Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.
Gilead Sciences (GILD) Stock Moves -0.44%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $76.42, moving -0.44% from the previous trading session.
Here's Why Lilly (LLY) Stock is Up Despite Coronavirus Crisis
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to rapid progress in its efforts to make medicines/antibodies to treat COVID-19.
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, Vale, Gilead Sciences, Kroger and Delek Logistics Partners
5 High Dividend-Yielding S&P 500 Stocks Amid Coronavirus Woes
by Swayta Shah
At a time when the coronavirus outbreak has hampered steady stream of income for many, investing in high dividend-yielding stocks can be rewarding. We have picked 5 S&P 500 stocks worth considering.
4 Solid Stocks to Buy on Renewed Hopes of Coronavirus Vaccine
by Ritujay Ghosh
The past few months have seen pharmaceutical companies making every effort to develop a vaccine for the novel coronavirus.
5 High Earnings Yield Stocks for a Winning Portfolio
by Zacks Equity Research
Earnings yield is very important in comparing a stock with other stocks and with fixed income securities. A stock with higher earnings yield fetches better returns.
Gilead's Coronavirus Drug Gets Conditional Approval in Europe
by Zacks Equity Research
Gilead (GILD) gets conditional marketing authorization for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection by the European Commission.
Gilead's Coronavirus Drug Being Stocked by the US Government
by Zacks Equity Research
Gilead's (GILD) coronavirus drug, remdesivir, is being stocked by the Trump administration through September.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
by Zacks Equity Research
Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $74.56, marking a -0.01% move from the previous day.
GILD vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
The Final Chapter of Chesapeake Energy Story?
by Mark Vickery
Finding difficulties in dealing with its now $10 billion in debt, fracking pioneer Chesapeake Energy (CHK) has announced it is filing for Chapter 11 bankruptcy protection.
Chesapeake Energy Files Chapter 11
by Zacks Equity Research
Chesapeake Energy Files Chapter 11
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
by Zacks Equity Research
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Invest in the Future With Megatrend ETFs
by Neena Mishra
These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.
Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III
by Zacks Equity Research
Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.
Gilead to Buy 49.9% Stake in Private Biotech for $275M
by Zacks Equity Research
Gilead (GILD) to purchase 49.9% equity interest in privately-held Pionyr Immunotherapeutics. The company can later also exercise an option to acquire the rest of Pionyr.
Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?